A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics.

ABSTRACT: Pharmacogenomics aims to correlate inter-individual differences of drug efficacy and/or toxicity with the underlying genetic composition, particularly in genes encoding for protein factors and enzymes involved in drug metabolism and transport. In several European populations, particularly in countries with lower income, information related to the prevalence of pharmacogenomic biomarkers is incomplete or lacking. Here, we have implemented the microattribution approach to assess the pharmacogenomic biomarkers allelic spectrum in 18 European populations, mostly from developing European countries, by analyzing 1,931 pharmacogenomics biomarkers in 231 genes. Our data show significant inter-population pharmacogenomic biomarker allele frequency differences, particularly in 7 clinically actionable

SUBMITTER: Mizzi C 

PROVIDER: S-EPMC5026342 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature